Literature DB >> 10426837

Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.

M L Kukin1, R S Freudenberger, M M Mannino, J Kalman, M Steinmetz, C Buchholz-Varley, O N Ocampo.   

Abstract

BACKGROUND: Initiation of beta-blocker therapy is often limited by worsening congestive heart failure, which may manifest as worsening hemodynamics. Deleterious hemodynamic effects might be mitigated with the vasodilation of combined calcium channel/beta-blocker therapy. METHODS AND
RESULTS: This prospective, randomized study assessed the safety and efficacy of metoprolol alone or combined with amlodipine on hemodynamic parameters at baseline, 2 hours after the first dose of study medication, and after 12 weeks of therapy in patients receiving background triple therapy for mild to severe heart failure. Functional, exercise, and hormonal status were assessed at baseline and end of study. Twenty-nine patients (mean age 50 +/- 12.1 years) were enrolled; 21 completed 12 weeks of treatment. Mean ejection fraction at baseline was 13.4% +/- 5.7%; 79% of patients had heart failure classified as New York Heart Association class III, and 66% had heart failure of idiopathic origin. Heart rate and blood pressure did not change with short-term therapy in either group. The first dose of both regimens produced significant increases in systemic vascular resistance and significant decreases in cardiac output and index and stroke volume and stroke work indexes; combination therapy acutely yielded small but statistically significant increases in pulmonary artery, pulmonary capillary wedge, and right atrial pressures. Long-term therapy with both regimens produced significant decreases in heart rate, systemic vascular resistance, and pulmonary capillary wedge pressure and significant increases in cardiac output and index and stroke volume and stroke work indexes. Combination therapy produced significant long-term decreases in blood pressure.
CONCLUSIONS: There was no further measurable benefit with the addition of amlodipine to metoprolol compared with the effects of metoprolol alone. Therapy with metoprolol alone and the combination of metoprolol and amlodipine was well tolerated in patients with mild to severe heart failure, as evidenced by a lack of adverse effects on hemodynamic parameters over the short term and clinical and hemodynamic improvement with long-term treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426837     DOI: 10.1016/s0002-8703(99)70110-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.

Authors:  K Brixius; A Bundkirchen; B Bölck; U Mehlhorn; R H Schwinger
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 2.  Metoprolol: a review of its use in chronic heart failure.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

3.  Initiation or maintenance of beta-blocker therapy in patients hospitalized for acute heart failure.

Authors:  Luiz Carlos Passos; Márcio Galvão Oliveira; Andre Rodrigues Duraes; Thiago Moreira Trindade; Andréa Cristina Costa Barbosa
Journal:  Int J Clin Pharm       Date:  2016-04-30

4.  The temporal hormesis of drug therapies.

Authors:  Noor Dudekula; Vikas Arora; Zsuzsanna Callaerts-Vegh; Richard A Bond
Journal:  Dose Response       Date:  2006-05-01       Impact factor: 2.658

5.  Wogonin Attenuates Isoprenaline-Induced Myocardial Hypertrophy in Mice by Suppressing the PI3K/Akt Pathway.

Authors:  Weichun Qian; Dongsheng Yu; Jia Zhang; Qiaoyun Hu; Chuanfeng Tang; Peiyu Liu; Peng Ye; Xiaoli Wang; Qiu Lv; Minglong Chen; Liang Sheng
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.